These guidelines summarize perspectives on the risk factors, diagnosis, and management of gastroparesis in adults (including dietary, pharmacological, device, and interventions directed at the pylorus), and they represent the official practice recommendations of the American College of Gastroenterology
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
New Discovered Adipokines Associated with the Pathogenesis of Obesity and Type 2 Diabetes
This review aims to summarize several adipokines discovered recently that have promising functions in obesity and T2DM. Among them, the levels of FSTL1, WISP1 and Asprosin in subjects with obesity or diabetes are commonly higher than in normal controls, suggesting that they may be pathogenic. Inversely, SFRP5, Metrnl, NRG4 and FAM19A5 may serve as the protective factors ( Diabetes, Metabolic Syndrome and Obesity)
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
Our study is limited to aggregate data. In a population of individuals with type 2 diabetes and a high CVD risk, the cardiovascular and renal benefits of SGLT2i remain substantial despite the risk of DKA and even the hypothetical risk of amputation (Diabetologia)
Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial
This study reveals common microbial responses in type 2 diabetes patients treated with two glucose-lowering drugs targeting the gut differently and acceptable performance of baseline gut microbiota in classifying individuals with different GLP-1 responses to vildagliptin. Our findings highlight bidirectional interactions between gut microbiota and glucose-lowering drugs (Diabetologia)
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
The aim of this review is to provide an in-depth summary of CVOT data—crystallising the key findings, from safety to efficacy—and to offer a practical perspective for physicians. Finally, we discuss the next steps for the post-CVOT era, with ongoing studies that may further transform clinical practice and improve outcomes for people with T2D, heart failure or renal disease (Cardiovascular Diabetology)
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI (NEJM)
Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy
Multiple medications are now accepted as being necessary to reduce albuminuria and decelerate the decline in renal function in the patient with diabetic nephropathy (Journal of Diabetes Research)
Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors
Several attributes influence how PwD take their medications. Insights gained directly from PwD have the potential to assist stakeholders in making more informed, patient-centered, treatment decisions, thus choosing and managing medications that PwD are comfortable initiating and persisting with over the longer term (Patient Preference and Adherence)
NHS To roll out life-changing glucose monitors to all Type 1 diabetes patients
NHS England patients with Type 1 diabetes will now be eligible for life-changing continuous glucose monitors after the health service secured a new cut-price deal (NHS England)
Diabetic retinopathy screening in the emerging era of artificial intelligence
Although clinically implemented AI-based diabetic retinopathy screening, integration of mobile devices and ocular telemedicine are still in their infancy, the technology is evolving rapidly and there is little doubt that these concepts will be able to optimise diabetic retinopathy screening within a few years (Diabetologia)
Depression, diabetes, comorbid depression and diabetes and risk of all-cause and cause-specific mortality: a prospective cohort study
We confirmed that depression and diabetes individually are associated with an increased mortality risk and also identified that comorbid depression and diabetes have synergistic effects on the risk of all-cause mortality that are largely driven by deaths from cancer and causes other than circulatory disease and cancer (Diabetologia)
Calcium-dependent transcriptional changes in human pancreatic islet cells reveal functional diversity in islet cell subtypes
Here we use our large-scale, multi-condition, single-cell dataset to show that human islets have cell-type-specific Ca2+-regulated gene expression profiles, some of them specific to subpopulations. In our dataset, we identify PCDH7 as a novel marker of beta cells having an increased number of Ca2+-regulated genes and enhanced insulin secretory function (Diabetologia)
Comparison of Insulin Dose Adjustments Made by Artificial Intelligence-Based Decision Support Systems and by Physicians in People with Type 1 Diabetes Using Multiple Daily Injections Therapy
Recommendations for insulin dose adjustments made by automatization did not differ significantly from recommendations given by expert physicians regarding the direction of change (Diabetes Technology and Therapeutics)
Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: systematic review and meta-analysis
Our review suggests that inpatient management in the general ward with DPP4i and GLP1Ra is as effective and safe as management with insulin. More randomized studies are required to support these findings before they could be recommended as usual practice (Diabetes Research and Clinical Practice)
The WISDOM self-management intervention: a cost-effectiveness analysis to support the transformation of type 2 diabetes care in England
The WISDOM risk-stratification and education intervention for type 2 diabetes appears to be cost-effective compared to usual care by reducing diabetes complications (Diabetic Medicine)
Effect of a Comprehensive Telehealth Intervention vs Telemonitoring and Care Coordination in Patients With Persistently Poor Type 2 Diabetes Control
This randomized clinical trial found that compared with telemonitoring/care coordination, comprehensive telehealth improved multiple outcomes in patients with PPDM at a reasonable additional cost. This study supports consideration of comprehensive telehealth implementation for PPDM in systems with appropriate infrastructure and may enhance the value of telehealth during the COVID-19 pandemic and beyond (JAMA)
Perioperative Fully Closed-Loop Insulin Delivery in Patients Undergoing Elective Surgery: An Open-Label, Randomized Controlled Trial
In the context of mixed elective surgery, the use of fully closed-loop subcutaneous insulin delivery improves glucose control without a higher risk of hypoglycemia (Diabetes Care)
Increased Serum Trimethylamine N-Oxide Level in Type 2 Diabetic Patients with Mild Cognitive Impairment
Our study showed that T2DM patients with MCI have elevated serum TMAO levels (Metabolic Syndrome and Obesity)
Diabetes: putting people at the heart of services
Diabetes is one of the fastest-growing health challenges of the 21st century. It requires constant self-management and regular contact with healthcare services throughout life. Effective ways to prevent type 2 diabetes, and to manage type 1 and type 2, are available. But more needs to be done to understand how to engage people with services, and how to target care to those who need it most (NIHR)
Tirzepatide Once Weekly for the Treatment of Obesity
In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight (NEJM)
- 1
- 2
- 3
- …
- 241
- Next Page »
Glycosmedia is also available as an App: